Enzon Pharmaceuticals, Inc. plans to consolidate its manufacturing operations in Indianapolis from its South Plainfield, NJ facility. The closing of the NJ facility is expected to impact approximately 50 employees. The company plans to assist them in their transition, and expects total restructuring charges of between $8 and $10 million associated with the transition, as well as a write-off of an estimated $8 million related to the leased facility in 2008. This consolidation is part of the ...